Imbruvica is a breakthrough drug used to treat chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, and mantle cell lymphoma. It is one of the most effective treatments for these diseases, but many people don’t know who makes it. In this article, we will take a look at the company behind Imbruvica and how this breakthrough drug is helping so many people.
Imbruvica is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is manufactured by Pharmacyclics LLC, an AbbVie company, a global research, and development based in Sunnyvale, California.
Who Makes Imbruvica?
Imbruvica is an oral medication used to treat certain types of cancer, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). It is manufactured by AbbVie, a global biopharmaceutical company based in North Chicago, Illinois.
History of the Drug
Imbruvica was initially developed by Pharmacyclics and its partner, Janssen Biotech, a subsidiary of Johnson & Johnson. The drug was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of CLL and MCL. In 2015, AbbVie acquired Pharmacyclics and the rights to Imbruvica.
How It Works
Imbruvica works by inhibiting the enzyme BTK (Bruton’s Tyrosine Kinase), which is involved in the growth and survival of malignant cells. By blocking BTK, Imbruvica can slow down the growth of cancer cells and help keep them from spreading.
Side Effects
Imbruvica can cause side effects, including:
- Nausea
- Diarrhea
- Fatigue
- Muscle and joint pain
- Headache
- Rash
- Low red blood cell and platelet counts
It is important to talk to your doctor about any side effects you experience while taking Imbruvica.
Top 6 Frequently Asked Questions
Who Makes Imbruvica?
Answer: Imbruvica is made by a joint venture between Janssen Biotech, Inc. and Pharmacyclics, LLC. Janssen Biotech, Inc. is a subsidiary of Johnson & Johnson, one of the world’s largest healthcare companies. Pharmacyclics, LLC is a biopharmaceutical company based in Sunnyvale, California that has been researching and developing innovative therapies for cancer and other serious diseases for more than 25 years.
What Type of Drug is Imbruvica?
Answer: Imbruvica is an oral small molecule inhibitor of Bruton tyrosine kinase (BTK). BTK is a protein that plays a role in the survival of B-cell lymphocytes and other immune functions. By inhibiting BTK, Imbruvica helps to reduce the activity of the immune system and can be used to treat certain types of cancer and other conditions.
What is Imbruvica Used to Treat?
Answer: Imbruvica is approved to treat certain types of cancer, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and marginal zone lymphoma (MZL). It is also approved to treat certain types of autoimmune disorders, such as rheumatoid arthritis (RA) and Crohn’s disease.
What are the Side Effects of Imbruvica?
Answer: Common side effects of Imbruvica include nausea, diarrhea, fatigue, muscle pain, fever, cough, and rash. More serious side effects can include liver problems, anemia, hemorrhage, and certain types of infections. Patients should talk to their doctor about any side effects they experience while taking Imbruvica.
How is Imbruvica Taken?
Answer: Imbruvica is taken orally as a once-daily tablet. It is typically taken with food and should be taken at the same time each day. Patients should follow their doctor’s instructions when taking Imbruvica and should not stop or change their dosage without consulting their doctor.
What Are the Benefits of Taking Imbruvica?
Answer: Imbruvica has been shown to be effective in treating certain types of cancer, autoimmune disorders, and other conditions. It is also generally well-tolerated and has fewer side effects than other treatments. Additionally, Imbruvica is taken orally as a once-daily tablet, which makes it easy to take and remember.
Imbruvica is a revolutionary drug that has made a major impact on the world of cancer treatment. Developed by Pharmacyclics and Janssen Biotech, the drug has been proven to be a powerful and effective treatment for many forms of cancer. It has been approved by the FDA, and Pharmacyclics and Janssen Biotech are both proud of their role in developing this life-saving medication. The success of Imbruvica is a testament to the dedication and hard work of these two companies in finding an effective way to fight cancer.